Brian Corvese

Insider Reports History

Entity
Individual
Location
C/O Antigenics Inc., 162 Fifth Avenue, Suite 900, New York, New York
Signature
By: /s/ Christine Klaskin, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Brian Corvese:

Stock Role Class Num Shares Value Price $ Report Date Ownership
MiNK Therapeutics, Inc. Director Common Stock 405K $332K $0.82 Sep 3, 2024 Direct
Protagenic Therapeutics, Inc.\new Director PTIX Common stock Options 43.8K $76.1K $1.74 Mar 25, 2024 Direct
AGENUS INC Director Stock Option 750 Jun 11, 2024 Direct

Insider Reports Filed by Brian Corvese

Symbol Company Period Transactions Value $ Form Type Date Filed Role
INKT MiNK Therapeutics, Inc. Sep 3, 2024 1 $17.9K 4 Sep 5, 2024 Director
AGEN AGENUS INC Jun 11, 2024 1 $0 4 Jun 18, 2024 Director
INKT MiNK Therapeutics, Inc. Jun 3, 2024 1 $17.8K 4 Jun 5, 2024 Director
PTIX Protagenic Therapeutics, Inc.\new Mar 25, 2024 1 $76.1K 4 Mar 29, 2024 Director
INKT MiNK Therapeutics, Inc. Mar 1, 2024 1 $17.9K 4 Mar 5, 2024 Director
AGEN AGENUS INC Feb 5, 2024 1 $0 4 Apr 22, 2024 Director
INKT MiNK Therapeutics, Inc. Dec 1, 2023 1 $17.9K 4 Dec 5, 2023 Director
INKT MiNK Therapeutics, Inc. Sep 1, 2023 1 $17.9K 4 Sep 6, 2023 Director
INKT MiNK Therapeutics, Inc. Jun 14, 2023 1 $0 4 Jun 16, 2023 Director
INKT MiNK Therapeutics, Inc. Jun 1, 2023 1 $17.9K 4 Jun 2, 2023 Director
INKT MiNK Therapeutics, Inc. Mar 1, 2023 1 $17.9K 4 Mar 3, 2023 Director
INKT MiNK Therapeutics, Inc. Dec 1, 2022 1 $17.9K 4 Dec 5, 2022 Director
INKT MiNK Therapeutics, Inc. Sep 15, 2022 1 $35.8K 4 Sep 19, 2022 Director
INKT MiNK Therapeutics, Inc. Mar 9, 2022 1 $0 4 Mar 11, 2022 Director
AGEN AGENUS INC Feb 4, 2022 1 $0 4 Feb 8, 2022 Director
INKT MiNK Therapeutics, Inc. Oct 13, 2021 0 $0 3 Oct 20, 2021 Director
AGEN AGENUS INC Jun 16, 2021 2 $0 4 Jun 21, 2021 Director
AGEN AGENUS INC Jun 15, 2021 1 $0 4 Jul 2, 2021 Director